JASON P KELLOGG
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
- Where
- IRVINE, CA
- NPI
- 1952331530
- Received
- $2,722,584 in 3,397 records, 2019 to 2025
- As principal investigator
- $322,433 of research payments to others in 169 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 516 | $463,034 |
| 2024 | General payment | 540 | $432,271 |
| 2023 | General payment | 496 | $428,922 |
| 2022 | General payment | 420 | $362,620 |
| 2021 | General payment | 316 | $252,722 |
| 2020 | General payment | 257 | $197,915 |
| 2019 | General payment | 852 | $585,096 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 953 | $2,094,267 |
| Travel and Lodging | 1,101 | $348,964 |
| Consulting Fee | 73 | $211,269 |
| Food and Beverage | 1,267 | $65,898 |
| Honoraria | 2 | $2,137 |
| Education | 1 | $46 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-22 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-22 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-22 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $324 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-22 | Neurocrine BioSciences, Inc. | $297 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-12-22 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $277 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-22 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $195 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-22 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $182 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-22 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-19 | ACADIA Pharmaceuticals Inc | $77 | Travel and Lodging | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-12-19 | ACADIA Pharmaceuticals Inc | $64 | Travel and Lodging | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-12-19 | ACADIA Pharmaceuticals Inc | $63 | Travel and Lodging | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-12-19 | ACADIA Pharmaceuticals Inc | $61 | Travel and Lodging | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-12-19 | ACADIA Pharmaceuticals Inc | $8 | Food and Beverage | Cash or cash equivalent | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-12-17 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,440 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-17 | Vanda Pharmaceuticals Inc. | $2,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-12-17 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-17 | Janssen Pharmaceuticals, Inc | $915 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-12-17 | Vanda Pharmaceuticals Inc. | $559 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-12-17 | Vanda Pharmaceuticals Inc. | $27 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-12-16 | ACADIA Pharmaceuticals Inc | $447 | Travel and Lodging | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-12-16 | ACADIA Pharmaceuticals Inc | $426 | Travel and Lodging | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-12-16 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $350 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-16 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $279 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-15 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $123 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-15 | E.R. Squibb & Sons, L.L.C. | $41 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-12-12 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-12 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-11 | Lundbeck LLC | $20 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-12-11 | Otsuka America Pharmaceutical, Inc. | $11 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-12-10 | ACADIA Pharmaceuticals Inc | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-12-10 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,665 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-10 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $129 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-10 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $128 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-10 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $9 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-09 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $119 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-08 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-05 | ACADIA Pharmaceuticals Inc | $120 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-12-04 | ACADIA Pharmaceuticals Inc | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-12-02 | Neurocrine BioSciences, Inc. | $3,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-12-02 | Neurocrine BioSciences, Inc. | $469 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-12-02 | Neurocrine BioSciences, Inc. | $199 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-12-02 | Neurocrine BioSciences, Inc. | $146 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-12-01 | Vanda Pharmaceuticals Inc. | $2,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-12-01 | ACADIA Pharmaceuticals Inc | $1,210 | Travel and Lodging | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-12-01 | Vanda Pharmaceuticals Inc. | $881 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-12-01 | Vanda Pharmaceuticals Inc. | $29 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-26 | Neurocrine BioSciences, Inc. | $3,800 | Consulting Fee | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-26 | E.R. Squibb & Sons, L.L.C. | $340 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-26 | E.R. Squibb & Sons, L.L.C. | $119 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-25 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-25 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $272 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-25 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $209 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-25 | ACADIA Pharmaceuticals Inc | $123 | Travel and Lodging | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-11-25 | ACADIA Pharmaceuticals Inc | $46 | Travel and Lodging | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-11-24 | Teva Pharmaceuticals USA, Inc. | $1,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-11-20 | Vanda Pharmaceuticals Inc. | $3,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-20 | E.R. Squibb & Sons, L.L.C. | $3,323 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-20 | Vanda Pharmaceuticals Inc. | $1,119 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-20 | Vanda Pharmaceuticals Inc. | $123 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-20 | ACADIA Pharmaceuticals Inc | $55 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-11-20 | E.R. Squibb & Sons, L.L.C. | $35 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-20 | Otsuka America Pharmaceutical, Inc. | $8 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-11-20 | Otsuka America Pharmaceutical, Inc. | $1 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-11-19 | Otsuka America Pharmaceutical, Inc. | $3,724 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-11-19 | Otsuka America Pharmaceutical, Inc. | $764 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-11-18 | Neurocrine BioSciences, Inc. | $3,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-18 | Vanda Pharmaceuticals Inc. | $2,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-18 | Vanda Pharmaceuticals Inc. | $566 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-18 | Neurocrine BioSciences, Inc. | $346 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-18 | ACADIA Pharmaceuticals Inc | $132 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-11-18 | Vanda Pharmaceuticals Inc. | $30 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-17 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,440 | Consulting Fee | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-14 | ACADIA Pharmaceuticals Inc | $99 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-11-13 | Otsuka America Pharmaceutical, Inc. | $918 | Travel and Lodging | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-11-13 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $27 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-13 | Neurocrine BioSciences, Inc. | $1 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-12 | Teva Pharmaceuticals USA, Inc. | $4,226 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-11-12 | Teva Pharmaceuticals USA, Inc. | $825 | Travel and Lodging | Cash or cash equivalent | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-11-12 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $231 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-12 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $186 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-12 | Teva Pharmaceuticals USA, Inc. | $90 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-11-12 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $68 | Food and Beverage | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-12 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-11 | E.R. Squibb & Sons, L.L.C. | $3,876 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-11 | Otsuka America Pharmaceutical, Inc. | $121 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-11-10 | Vanda Pharmaceuticals Inc. | $22 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-11-07 | E.R. Squibb & Sons, L.L.C. | $260 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-07 | E.R. Squibb & Sons, L.L.C. | $38 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-06 | E.R. Squibb & Sons, L.L.C. | $825 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-03 | E.R. Squibb & Sons, L.L.C. | $4,984 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-01 | ACADIA Pharmaceuticals Inc | $616 | Travel and Lodging | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-10-31 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $182 | Travel and Lodging | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-31 | Neurocrine BioSciences, Inc. | $19 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-10-30 | Neurocrine BioSciences, Inc. | $3,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-10-30 | Neurocrine BioSciences, Inc. | $371 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-10-30 | Neurocrine BioSciences, Inc. | $355 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-10-30 | Neurocrine BioSciences, Inc. | $158 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-10-29 | E.R. Squibb & Sons, L.L.C. | $950 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-29 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3 | Food and Beverage | Cash or cash equivalent | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-27 | ACADIA Pharmaceuticals Inc | $51 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-10-27 | ACADIA Pharmaceuticals Inc | $16 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-10-25 | ACADIA Pharmaceuticals Inc | $12 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-10-22 | Otsuka America Pharmaceutical, Inc. | $100 | Travel and Lodging | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-22 | Otsuka America Pharmaceutical, Inc. | $99 | Travel and Lodging | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-22 | Otsuka America Pharmaceutical, Inc. | $61 | Travel and Lodging | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-22 | Otsuka America Pharmaceutical, Inc. | $47 | Travel and Lodging | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-22 | Otsuka America Pharmaceutical, Inc. | $47 | Travel and Lodging | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-21 | E.R. Squibb & Sons, L.L.C. | $434 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-21 | E.R. Squibb & Sons, L.L.C. | $349 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-21 | Otsuka America Pharmaceutical, Inc. | $341 | Travel and Lodging | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-21 | E.R. Squibb & Sons, L.L.C. | $299 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-20 | Vanda Pharmaceuticals Inc. | $3,120 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-20 | Vanda Pharmaceuticals Inc. | $437 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-20 | Vanda Pharmaceuticals Inc. | $58 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-17 | Otsuka America Pharmaceutical, Inc. | $326 | Travel and Lodging | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-17 | Otsuka America Pharmaceutical, Inc. | $157 | Travel and Lodging | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-17 | Otsuka America Pharmaceutical, Inc. | $108 | Travel and Lodging | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-17 | Otsuka America Pharmaceutical, Inc. | $89 | Travel and Lodging | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-17 | Otsuka America Pharmaceutical, Inc. | $6 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-15 | Otsuka America Pharmaceutical, Inc. | $4,312 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-14 | Vanda Pharmaceuticals Inc. | $2,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-14 | Vanda Pharmaceuticals Inc. | $844 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-14 | Vanda Pharmaceuticals Inc. | $23 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-10 | Otsuka America Pharmaceutical, Inc. | $246 | Travel and Lodging | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $779 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $326 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $134 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $64 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $51 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $49 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $29 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $29 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-08 | Otsuka America Pharmaceutical, Inc. | $260 | Travel and Lodging | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-08 | Otsuka America Pharmaceutical, Inc. | $124 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-06 | Vanda Pharmaceuticals Inc. | $2,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-06 | Teva Pharmaceuticals USA, Inc. | $99 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2025 | |
| 2025-10-06 | Vanda Pharmaceuticals Inc. | $35 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-06 | Vanda Pharmaceuticals Inc. | $12 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $525 | Travel and Lodging | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $275 | Travel and Lodging | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $138 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $91 | Travel and Lodging | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $59 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $52 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $46 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $44 | Travel and Lodging | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-02 | Vanda Pharmaceuticals Inc. | $2,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-02 | Vanda Pharmaceuticals Inc. | $21 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-02 | Vanda Pharmaceuticals Inc. | $15 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-02 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-09-27 | Otsuka America Pharmaceutical, Inc. | $4,312 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-09-26 | Neurocrine BioSciences, Inc. | $3,088 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-26 | Otsuka America Pharmaceutical, Inc. | $260 | Travel and Lodging | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-09-26 | Neurocrine BioSciences, Inc. | $159 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-25 | E.R. Squibb & Sons, L.L.C. | $1,938 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-24 | Otsuka America Pharmaceutical, Inc. | $121 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-09-23 | Neurocrine BioSciences, Inc. | $4,513 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-23 | Neurocrine BioSciences, Inc. | $383 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-23 | Neurocrine BioSciences, Inc. | $336 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-23 | Neurocrine BioSciences, Inc. | $326 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-23 | Neurocrine BioSciences, Inc. | $225 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-23 | Neurocrine BioSciences, Inc. | $220 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-23 | Neurocrine BioSciences, Inc. | $120 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-23 | Neurocrine BioSciences, Inc. | $89 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-23 | Neurocrine BioSciences, Inc. | $34 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-23 | Neurocrine BioSciences, Inc. | $22 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-19 | Neurocrine BioSciences, Inc. | $3,088 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-19 | Neurocrine BioSciences, Inc. | $246 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-19 | Neurocrine BioSciences, Inc. | $139 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-19 | Neurocrine BioSciences, Inc. | $80 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-18 | Neurocrine BioSciences, Inc. | $5,225 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-18 | Neurocrine BioSciences, Inc. | $3,088 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-18 | Neurocrine BioSciences, Inc. | $723 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-18 | Neurocrine BioSciences, Inc. | $641 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-18 | Neurocrine BioSciences, Inc. | $336 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-18 | Neurocrine BioSciences, Inc. | $256 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-18 | Neurocrine BioSciences, Inc. | $203 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-18 | Neurocrine BioSciences, Inc. | $55 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-18 | Neurocrine BioSciences, Inc. | $47 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-18 | Neurocrine BioSciences, Inc. | $16 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-18 | Neurocrine BioSciences, Inc. | $15 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-17 | Neurocrine BioSciences, Inc. | $1,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-16 | Vanda Pharmaceuticals Inc. | $2,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-09-16 | Vanda Pharmaceuticals Inc. | $2,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-09-16 | Vanda Pharmaceuticals Inc. | $124 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-09-16 | Vanda Pharmaceuticals Inc. | $29 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-09-16 | Vanda Pharmaceuticals Inc. | $5 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-09-11 | Otsuka America Pharmaceutical, Inc. | $14 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-09-10 | Vanda Pharmaceuticals Inc. | $2,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-09-10 | Vanda Pharmaceuticals Inc. | $869 | Travel and Lodging | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-09-10 | Vanda Pharmaceuticals Inc. | $39 | Food and Beverage | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-09-09 | Neurocrine BioSciences, Inc. | $3,088 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-09 | Neurocrine BioSciences, Inc. | $190 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-09 | Neurocrine BioSciences, Inc. | $164 | Travel and Lodging | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-09 | Neurocrine BioSciences, Inc. | $139 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-08 | Janssen Pharmaceuticals, Inc | $3,510 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-09-08 | Janssen Pharmaceuticals, Inc | $716 | Travel and Lodging | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-09-05 | Vanda Pharmaceuticals Inc. | $2,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FANAPT Drug, SCHIZOPHRENIA | 2025 |
The latest 200 records of 3,397.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2021-12-31 | Allergan, Inc. | GLOBAL CLINICAL TRIALS | $550 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-10-13 | Allergan, Inc. | GLOBAL CLINICAL TRIALS | $1,581 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-06-09 | Allergan, Inc. | GLOBAL CLINICAL TRIALS | $177 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-02-04 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $2,573 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2021 |
| 2021-02-04 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $21,445 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2021 |
| 2021-01-27 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $3,513 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2021 |
| 2020-12-31 | Allergan, Inc. | GLOBAL CLINICAL TRIALS | $600 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2020 |
| 2020-12-02 | Eli Lilly and Company | GLOBAL CLINICAL TRIALS | $878 | A STUDY OF HEALTH CARE USE AND COSTS IN PARTICIPANTS WITH EARLY STAGE ALZHEIMER'S DISEASE AD GERAS US | 2020 |
| 2020-10-08 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $1,962 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2020 |
| 2020-08-13 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $625 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2020 |
| 2020-08-13 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $875 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2020 |
| 2020-08-13 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $1,375 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2020 |
| 2020-08-13 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $1,625 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2020 |
| 2020-08-13 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $1,625 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2020 |
| 2020-07-30 | Allergan, Inc. | COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | $86 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2020 |
| 2020-07-28 | Allergan, Inc. | COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | $700 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2020 |
| 2020-07-28 | Allergan, Inc. | COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | $169 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2020 |
| 2020-07-23 | Otsuka Pharmaceutical Development & Commercialization, Inc. | GLOBAL CLINICAL TRIALS LLC | $7,000 | A 12-WEEK, MULTICENTER, ACTIVE-TREATMENT EXTENSION TRIAL TO EVAULATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE | 2020 |
| 2020-07-22 | Allergan, Inc. | GLOBAL CLINICAL TRIALS | $3,377 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2020 |
| 2020-06-11 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $330 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $148 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $219 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $219 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $16 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $16 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $176 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $176 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $183 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $183 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $147 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $147 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $147 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $147 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $28 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $28 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $28 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $28 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $253 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $253 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $128 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $128 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $148 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $148 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $128 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $128 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $168 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $168 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $168 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $168 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $247 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $140 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $140 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $140 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $140 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $211 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $211 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $211 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $28 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $28 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $28 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $28 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $156 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $156 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $156 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $169 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $183 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $183 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $183 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $28 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $28 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $28 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $28 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $253 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $253 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $247 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $105 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $16 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $197 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $197 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $197 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $197 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $148 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $148 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $148 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $148 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-29 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $148 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-05-28 | Otsuka Pharmaceutical Development & Commercialization, Inc. | GLOBAL CLINICAL TRIALS LLC | $4,789 | A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE E | 2020 |
| 2020-05-27 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $1,962 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2020 |
| 2020-04-01 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $4,531 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2020 |
| 2020-02-19 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $9,420 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2020 |
| 2020-01-18 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $152 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-01-18 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $152 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2020 |
| 2020-01-17 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $5,106 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2020 |
| 2020-01-09 | Neurocrine BioSciences, Inc. | GLOBAL CLINICAL TRIALS LLC | $17,425 | A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE POTENTIAL FOR CLINICAL DEPENDENCE AND WITH | 2020 |
| 2019-12-31 | Allergan, Inc. | GLOBAL CLINICAL TRIALS | $1,683 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2019 |
| 2019-12-18 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $1,464 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2019 |
| 2019-12-18 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $2,162 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2019 |
| 2019-12-14 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS | $1,974 | An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyski | 2019 |
| 2019-12-06 | Genentech, Inc. | GLOBAL CLINICAL TRIALS | $1,350 | GANTENERUMAB IN EARLY AD | 2019 |
| 2019-12-05 | Teva Pharmaceuticals USA, Inc. | GLOBAL CLINICAL TRIALS LLC | $1,464 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Irvine, CA, county Orange County, CA, state California; placed by its city name.
| Measure | Place (city or town) Irvine, CA | County Orange County, CA | State California |
|---|---|---|---|
| Population B01003 | 311,690 | 3,165,820 | 39,287,377 |
| Population, 2020 census P1 | 307,670 | 3,186,989 | 39,538,223 |
| Median age B01002 | 34.0 | 39.4 | 37.9 |
| Under 18 B01001 | 21.7% | 21.0% | 22.0% |
| 65 and over B01001 | 10.8% | 16.3% | 15.7% |
| Households B11001 | 112,091 | 1,082,960 | 13,548,091 |
| Foreign born B05002 | 39.8% | 30.4% | 27.0% |
| Median household income B19013 | $136,719 | $116,289 | $99,122 |
| Median family income B19113 | $167,999 | $132,827 | $113,346 |
| Per capita income B19301 | $64,055 | $54,557 | $49,513 |
| Poverty rate B17001 | 10.8% | 9.5% | 12.0% |
| Unemployment rate B23025 | 5.9% | 5.4% | 6.6% |
| Civilian labor force B23025 | 168,889 | 1,692,091 | 20,068,466 |
| Mean commute (minutes) B08013 | 24.7 | 26.7 | 28.7 |
| Bachelor's degree or higher B15003 | 70.6% | 44.1% | 37.1% |
| Housing units B25001 | 120,206 | 1,146,169 | 14,644,735 |
| Owner-occupied B25003 | 44.5% | 56.4% | 55.9% |
| Renters B25003 | 55.5% | 43.6% | 44.1% |
| Median home value B25077 | $1,191,500 | $962,600 | $734,700 |
| Median gross rent B25064 | $2,997 | $2,434 | $2,036 |
| White, not Hispanic B03002 | 34.3% | 36.9% | 33.8% |
| Black B03002 | 1.9% | 1.5% | 5.2% |
| Hispanic or Latino B03002 | 11.4% | 34.2% | 40.2% |
| Asian B03002 | 44.6% | 22.2% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Irvine, CA.
Comments